Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Omar Butt
Publisher Correction: Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial
Correction to: Nature Cancer https://doi.org/10.1038/s43018-026-01163-w, published online 12 May 2026. In the version of the article initially published, in the top-left graph of Fig. 3b, the y-axis label was “CD4+CD69+ (%, delta)” but should have been “CD8+CD69+ (%, delta)”. In the top-right box of Fig. 5d, the label “Post-GNOS-PV01” should have read “Pre-GNOS-PV01”. These corrections have been made to the HTML and PDF versions of the article.
Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial
|
Abstract Glioblastoma is a fatal disease with a median prognosis of 12–18 months. Recent studies have shown encouraging results using neoantigen-based vaccines to stimulate glioblastoma-directed immune responses, but overall immunogenicity has been low.
By Elizabeth A. R. Garfinkle, Renzo Perales-Linares, Ryan C Gimple, Alexandra J. Livingstone, Kaleigh Roberts, Omar Butt, S. Peter Goedegebuure, Michael McLellan, Gue Su Chang, Jasreet Hundal, Jian Yan, Jaye B. Navarro, Sophia A. Paxton, Srestha Chattopadhyay, Neil Cooch, Alfredo Perales-Puchalt, Konstantina Stavroulaki, Sarah Rochestie, Joann Peters, Beth Junker, Jian L. Campian, Milan G. Chheda, Michael R. Chicoine, Albert Kim, Jon Willie, Gregory J. Zipfel, Joshua Dowling Verified, Christopher Miller Verified, Obi L. Griffith, Malachi Griffith, William E. Gillanders, Katherine Miller Verified, Elaine R. Mardis, Niranjan Y. Sardesai, Gavin P. Dunn, Tanner Johanns
|
Nature
Verified
Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial - Nature Communications
|
Abstract Immune checkpoint inhibitors (ICIs) show minimal efficacy in recurrent high-grade astrocytoma (rHGA). Laser interstitial thermal therapy (LITT), a minimally invasive cytoreductive approach, may prime rHGA for ICI response. A phase 1/randomized phase 2b trial (ClinicalTrials.gov: NCT02311582) was designed to test pembrolizumab in combination with LITT in patients with rHGA. Nine patients were enrolled in the phase I dose-escalation lead-in study.
By Jian L. Campian, Son Le, Sơn Lê, Ashley Ghiaseddin, Omar Butt, Dongjiang Chen, Yifei Xu, Jingxia Liu, Maryam Rahman, William A. Leidig, George Ansstas, Alice Zhou, Sangami Pugazenthi, Gavin P. Dunn, Jiayi Huang, Milan G. Chheda, Albert Kim, Eric C. Leuthardt, David Tran, David Trần, Harshit Manektalia, Nathan Thai, Tanner Johanns
|
Nature
Verified
Alice Zhou, MD, PhD, and Omar Butt, MD, PhD, on Surprising Associations With Neurotoxicity and Neurofilament Light
The medical oncologists at Washington University School of Medicine in St. Louis discussed surprising findings from their retrospective study. The risk of developing immune effector cell–associated neurotoxicity syndrome (ICANS) is associated with plasma neurofilament light chain (NfL) levels in patients treated with chimeric antigen receptor (CAR) T-cell therapy, according to a paper published in JAMA Oncology.
Alice Zhou, MD, PhD, and Omar Butt, MD, PhD, on Investigating Associations With CAR T Toxicities
The medical oncologists at Washington University School of Medicine in St. Louis discussed background to their research on associations between neurofilament light and neurotoxicity. Patients treated with chimeric antigen receptor (CAR) T-cell therapy’s risk of developing immune effector cell–associated neurotoxicity syndrome (ICANS) is associated with plasma neurofilament light chain (NfL) levels, according to a paper published in JAMA Oncology. First author Omar H.
Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell-Associated Neurotoxicity Syndrome | Cancer Biomarkers | JAMA Oncology | JAMA Network
Key Points Question How early are elevations in plasma neurofilament light chain (NfL) levels observed before the development of neurotoxicity after chimeric antigen receptor T-cell therapy? Findings In this cross-sectional study of 30 patients undergoing cellular therapy, NfL levels were elevated in patients who developed immune effector cell–associated neurotoxicity syndrome (ICANS) at baseline (preinfusion) and remained elevated for 30 days.
Managing the wealth of PE clients: simple solutions for complex times
Over the course of the past few months, much has been written about private equity in the national press from plunging deal volumes, to the debate around portfolio access to government financing schemes and the levels of leverage, dry powder and more. But the impact of these on the industry’s professionals is much more nuanced. So what are our clients – comprising more than 900 partners and senior principals in more than 120 of the world’s leading private equity firms – asking us?
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Omar
Contact Omar, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack